DDInter980 DDInter1376
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Isavuconazonium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Isavuconazonium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Isavuconazonium {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Isavuconazonium {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Loratadine
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Isavuconazonium may lead to a major life threatening interaction when taken with Apalutamide
Isavuconazonium may lead to a major life threatening interaction when taken with Cobimetinib